|
Gonadorelin for Injection
» Gonadorelin for Injection is a sterile mixture of Gonadorelin Hydrochloride with suitable diluents. It contains the equivalent of not less than 90.0 percent and not more than 115.0 percent of the labeled amount of gonadorelin (C55H75N17O13).
Packaging and storage
Preserve in tight, well-sealed containers.
Identification
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Constituted solution
At the time of use, it meets the requirements for Constituted Solutions under Injections
Bacterial endotoxins
pH
Other requirements
It meets the requirements for Sterility Tests
Assay
Buffer solution, Mobile phase, Standard preparations, Chromatographic system, and Identification solution
Proceed as directed in the Assay under Gonadorelin Hydrochloride.
Assay preparation
Separately dissolve the contents of not less than 5 vials of Gonadorelin for Injection in Mobile phase to obtain a concentration of 100 µg of gonadorelin per mL. Place the vials in an ultrasonic bath for 5 minutes, and allow to cool at room temperature. Combine the solutions in the vials to obtain the Assay preparation.
Procedure
Proceed as directed in the Assay under Gonadorelin Hydrochloride. Plot the responses of the gonadorelin peaks versus concentration, in mg per mL, of gonadorelin in each of the Standard preparation. Calculate the quantity of gonadorelin (C55H75N17O13) in the Gonadorelin for Injection taken for the Assay preparation by the formula:
(1182.33 / 1255.4)(C)(V + 0.06)
in which 1182.33 and 1255.4 are the molecular weights of gonadorelin and gonadorelin hydrochloride, respectively; C is the concentration of gonadorelin in the Assay preparation as obtained from the regression line; V is the volume, in mL, of Mobile phase used to prepare the Assay preparation; and 0.06 is the correction factor for the volume created by the dissolved test specimen.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP32NF27 Page 2522
|